Francesco de Rubertis is Director at Centessa Pharmaceuticals plc (CNTA). They have made 7 open-market trades across 2 companies since 2014, most recently 2022-03-21.
CIK 0001601521
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $27.5M since 2014, against 1 sale. Across 6 scored buys the stock is down 18.5% at ninety days, and 16.5 points behind the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 17% | 0% | 0% |
| Avg Move | -10.2% | -8.9% | -18.5% |
| Alpha | -8.8% | -10.7% | -16.5% |
| Scored | 6 | 6 | 6 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CNTA | BUY | 2021-12-02 | 2021-12-06 | $12.82 | $870K | -12.6% | -22.4% | -40.7% |
| CNTA | BUY | 2021-11-30 | 2021-12-02 | $12.24 | $2.4M | -15.9% | -12.2% | -33.3% |
| CNTA | BUY | 2021-11-26 | 2021-11-30 | $11.64 | $1.6M | +1.8% | -3.2% | -26.5% |
| CNTA | BUY | 2021-06-02 | 2021-06-04 | $20.00 | $12.0M | -1.4% | -11.6% | -6.6% |
| NERV | SELL | 2016-08-10 | 2016-08-12 | $10.00 | $10.0M | +2.8% | +10.0% | +0.4% |
| NERV | BUY | 2015-03-18 | 2015-03-20 | $4.81 | $975K | -16.7% | -2.0% | -2.0% |
| NERV | BUY | 2014-07-07 | 2014-07-09 | $6.00 | $9.7M | -16.7% | -2.0% | -2.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.